This article was originally published in Start Up
Thiakis Ltd., a spin-out of Imperial College in London, aims to commercialize an effective anti-obesity treatment based on a peptide hormone called oxyntomodulin, which is released primarily by the intestines after food is consumed, and seems to rein in appetite.
You may also be interested in...
The unanimous rejection of Sanofi-Aventis' obesity drug rimonabant by an FDA Advisory Committee in June hasn't put off the host of firms, large and small, seeking an answer to the obesity epidemic. Despite the many drug casualties in this area, still, it seems, no approach is ruled out.
As VCs continue to woo later-stage assets, a new breed of companies has stepped in upstream to help UK universities commercialize their IP. The models vary, and it's unclear how successful they'll be either for investors, or for universities. But the attention and money they're attracting to the area are welcome.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.